CAMBRIDGE, Mass. — Prudentia Sciences announced it has raised $20 million in Series A financing to accelerate the development and adoption of its AI-native due diligence platform for life sciences dealmaking. The round was led by McKesson Ventures, with participation from SignalFire. Existing investors Iaso Ventures, Virtue, and GV also participated. The financing brings Prudentia’s total funding to $27 million, following a $7 million seed round completed in 2024.
Prudentia Sciences develops an AI-native platform designed to help pharmaceutical companies, biotechnology firms, and financial institutions evaluate breakthrough medicines with greater speed and rigor. By synthesizing complex clinical and scientific data into actionable insights, the platform is intended to accelerate deal throughput and support acquisition, licensing, and investment decisions made by business development, investment, and diligence teams.
The company’s approach combines artificial intelligence with human expertise, enabling structured collaboration among buyers, sellers, and intermediaries. This human-in-the-loop model is designed to provide a secure and compliant infrastructure for high-stakes investment decisions across the life sciences sector.
“Prudentia is modernizing the way life sciences organizations harness data to evaluate assets and proactively manage risk,” said Dave Schulte, president of McKesson Ventures. “Their AI-native platform accelerates scientific due diligence with real-time insights, seamless integration, and intelligent automation, transforming a traditionally fragmented process into a connected, agile, and future-ready workflow.”
Prudentia plans to use the new capital to expand its product capabilities, enhance intelligence across both technical and non-technical diligence workflows, and scale its commercial operations. The company also plans to expand its presence into the Asia-Pacific region and Europe.
The platform is designed to serve as a continuously updated source of truth for diligence, enabling teams to align more quickly and make high-stakes investment and partnering decisions with greater confidence using explainable AI.
“Life sciences dealmaking is inherently complex and time-intensive, with substantial capital and scientific innovation at stake,” said Sadiqa Mahmood, founder and chief executive officer of Prudentia Sciences. “Biotechs struggle to present their assets with clarity and rigor, while pharma teams are forced to balance speed with thorough diligence. Without an intelligent platform to bridge this gap, diligence remains fragmented and high-risk. Prudentia collapses the distance between technical data and strategic conviction, enabling teams to make confident go-or-no-go decisions in a fraction of the time.”
